Scynexis Bolsters Pipeline with SCY-770 Acquisition, Extends Cash Runway to 2029
Event summary
- Scynexis completed the acquisition of SCY-770 (formerly PXL-770) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
- A Phase 2 proof-of-concept study for SCY-770 is anticipated to begin in Q4 2026 with an early efficacy readout expected in the second half of 2027.
- Scynexis raised approximately $37.2 million in a private placement, extending its cash runway to mid-2029.
- GSK is committed to the relaunch of Brexafemme, with potential annual net sales milestones of up to $146 million for Scynexis.
The big picture
Scynexis's acquisition of SCY-770 and the subsequent funding round position the company to advance its pipeline in rare diseases. The strategic focus on ADPKD and antifungal treatments aligns with broader industry trends toward targeted therapies for genetic disorders. The extended cash runway provides a buffer for clinical development, but the company's success will hinge on the efficacy and commercial potential of its lead assets.
What we're watching
- Clinical Progress
- The pace at which SCY-770 advances through Phase 2 trials will determine its potential as a differentiated treatment for ADPKD.
- Financial Strategy
- Whether Scynexis can sustain its extended cash runway through mid-2029 while advancing multiple clinical programs.
- Commercialization
- How GSK's relaunch of Brexafemme will impact Scynexis's revenue milestones and market positioning.
Related topics